Navigation Links
Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
Date:8/6/2009

capital that we expect will allow us to continue to seek to internally develop CUDC-101, our first-in-class HDAC/EGFR/Her2 inhibitor that is currently enrolling patients in a Phase I dose escalation trial, as well as our other promising preclinical multi-targeted development programs. We believe that the up-front license fee and near-term contingent payments will extend our cash runway well into 2011."

"We expect additional data during the second half of 2010 from our collaborator Genentech's ongoing Phase II clinical trials of GDC-0449, a Hedgehog Pathway Inhibitor, in advanced basal cell carcinoma, metastatic colorectal cancer and advanced ovarian cancer," said Michael Gray, Curis' Chief Operating and Chief Financial Officer. "Positive results with GDC-0449 in any of these indications have the potential to be a significant value-creating event for Curis stockholders and could provide future milestone payments to further extend our cash runway and fund our further investment in our multi-targeted inhibitor programs, including CUDC-101."

"Debiopharm Group is very excited about this new opportunity. Curis has established its excellence in this type of targeted therapy, which has the potential of being effective in several cancer indications, alone or in combination with other drugs", said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group, who added: "The professionalism of the entire Curis team has made us very confident that the partnership would soon prove successful for the two parties and open the door to an outstanding cooperation to bring new and effective therapies to patients."

About Debiopharm Group

Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. It develops its products for global registration and maximum commercial potential. Once registered, the
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
2. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
3. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
4. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
5. Japanese Cancer Association and Debiopharm Honour Japanese Research
6. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
7. Debiopharm and EPFL Establish an Oncology Chair
8. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
9. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
10. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
11. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)...  Multiple new research abstracts suggest walnuts may have ... From their impact on colon cancer and certain aspects ... gut health and vascular health, the research findings presented ... of walnuts, inner workings. Running March 28 through April ... meeting attracts an international audience of over 14,000 leading ...
(Date:3/30/2015)... BRUNSWICK, N.J. , March 30, 2015  New ... and innovation projects in the state of ... its next round of grant funding, announced James ... New Jersey Health Foundation Research Grants program, an additional ... $35,000 each to fund early stage research projects that ...
(Date:3/30/2015)... - A new national Labour Market Information (LMI) report ... of new graduates entering the biotech sector. The BioTalent ... New Grads in Biotech," is sponsored in part by ... and features data collected from new graduates that participated ... 2013 to 2015. Among the interesting trends ...
(Date:3/30/2015)... USA (PRWEB) March 29, 2015 A ... the United States and plenary talks by four leading ... SPIE Optics + Optoelectronics next month in Prague, ... presentations in 17 conferences alongside a two-day exhibition. Sponsored ... photonics , the event will run 13-16 April in ...
Breaking Biology Technology:New Findings Support the Benefits of Eating Walnuts on Overall Health 2New Findings Support the Benefits of Eating Walnuts on Overall Health 3New Findings Support the Benefits of Eating Walnuts on Overall Health 4New Jersey Health Foundation Announces An Additional $1 Million To Fund Innovation and Research Grants in New Jersey 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 3New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3
... recent decision to pull Pfizer Cox-2 inhibitor Bextra from the marketplace ... up in the Merck Vioxx dilemma months ago and its stock ... $25 per share in February. It has recently moved up to ... about 30 percent in the last 12 months. , ,Though Pfizer ...
... Controls Inc., which makes auto parts and facility-control systems, reported ... on sales of $7.1 billion. , ,That's up from $158 ... quarter a year ago. , ,"We have faced unprecedented challenges ... result, have accelerated actions to help ensure our company's competitiveness," ...
... Accountability Act privacy deadline two years ago, the security ... compliance and many companies may not yet be compliant. ... HIPAA rule involves too many software protocols throughout the healthcare ... admitting that it can't comply with a guideline moves a ...
Cached Biology Technology:Why are new drugs failing? 2Why are new drugs failing? 3Why are new drugs failing? 4Why are new drugs failing? 5Why are new drugs failing? 6As HIPAA deadline passes even the unprepared are safe for now 2As HIPAA deadline passes even the unprepared are safe for now 3
(Date:3/23/2015)... , March 23, 2015  In the 2014 ... fraud case conviction losses. This figure accounts for a ... according to The Nilson Report, exceeds $11 billion globally. ... tool after a crime has occurred. Investor Mark ... polygraph expert Joe Paolella partnered to administer ...
(Date:3/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces its biometric ... the products featured in 2015 "I Want That" International ... EST on the DIY Network.   DIY,s ... , site of the 2015 International CES for ...
(Date:3/17/2015)... 2015 MedNet Solutions , a ... study management systems, is pleased to announce that ... Outsourcing in Clinical Trials Southeast conference – March ... excellent forum for MedNet to showcase iMedNet ... (SaaS) eClinical technology platform. We strongly ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... The history of evolution is periodically marked by explosions ... wide range of shapes and sizes. With a new ... record, researchers have discovered that these diversifications proceeded head-first. ... that diversified around the time of two separate extinction ...
... vegetables and fish gives a longer life. This is the ... Sahlgrenska Academy at the University of Gothenburg. Research studies ever ... on a high consumption of fish and vegetables and a ... leads to better health., Study on older people ...
... With $3.6 million in new federal funding, researchers ... Terrorism and Responses to Terrorism http://www.start.umd.edu/ >(START), ... to expand the scientific understanding of the human ... homeland security issues, such as terrorist behavior, violent ...
Cached Biology News:'Head-first' diversity shown to drive vertebrate evolution 2'Head-first' diversity shown to drive vertebrate evolution 3UMD's START gets $3.6 million to study terrorism's human causes and consequences 2UMD's START gets $3.6 million to study terrorism's human causes and consequences 3
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit polyclonal to Yaf9 ( Abpromise for all tested applications)....
... This product is designed to deparaffinize and ... formalin fixed paraffin-embedded tissue sections mounted on ... melting the paraffin at the high temperature ... with emulsification of the paraffin by detergent. ...
... U.S. sourced, ideal for those ... Low hemoglobin; Endotoxin: < 1.0 ... US origin; U.S. sourced, ideal ... uncompromising quality. Low hemoglobin Endotoxin: ...
Biology Products: